Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) in prostate cancer - An J, Sun Y-P, Adams J, Fisher M, Belldegrun A, Rettig MB, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA [J An, Y-PS, MF, MBR]; Millennium Pharmaceuticals, Inc., Cambridge, MA [J Adams]; and University of California at Los Angeles School of Medicine, Los Angeles, CA [AB, MBR].

Author: Chatta G.  

Publisher: Elsevier

ISSN: 1078-1439

Source: Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.6, 2003-11, pp. : 490-491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content